[Frequency of MSI, PD-L1 (CPS), HER2 in poorly cohesive gastric carcinomas].
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
600 patients with GC who underwent radical surgical treatment at the N.
I · Intervention 중재 / 시술
radical surgical treatment at the N
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Our study demonstrated that in diffuse and poorly cohesive/signet ring cell GC the frequency of occurrence of the above clinically significant tumor biomarkers is lower compared to intestinal/mixed GC.
[UNLABELLED] Gastric cancer (GC) is a heterogeneous tumor with various molecular changes.
APA
Nered SN, Torosyan RO, et al. (2025). [Frequency of MSI, PD-L1 (CPS), HER2 in poorly cohesive gastric carcinomas].. Arkhiv patologii, 87(2), 11-17. https://doi.org/10.17116/patol20258702111
MLA
Nered SN, et al.. "[Frequency of MSI, PD-L1 (CPS), HER2 in poorly cohesive gastric carcinomas].." Arkhiv patologii, vol. 87, no. 2, 2025, pp. 11-17.
PMID
40289427 ↗
Abstract 한글 요약
[UNLABELLED] Gastric cancer (GC) is a heterogeneous tumor with various molecular changes. An active search for molecular markers is crucial to determine the effectiveness of drug treatment and prognosis of the disease. Several biomarkers have the greatest clinical significance: HER2, MSI / dMMR, PD-L1 (CPS), EBV and Claudin 18.
[OBJECTIVE] To study the frequency of HER2, MSI / dMMR and PD-L1 (CPS) in patients with operable GC depending on the tumor type according to P. Lauren.
[MATERIAL AND METHODS] The study included 600 patients with GC who underwent radical surgical treatment at the N.N. Blokhin National Medical Research Center of Oncology from 2018 to 2023.
[RESULTS] In the study, the proportion of diffuse GC was 21.5% (120/600). HER2 overexpression was found in 5.2% (5/96) of cases with diffuse GC, 20.4% (37/181) of cases with intestinal GC, 10.1% (7/69) of cases with mixed GC (=0.0029). The incidence of MSI was 3.3% (4/120) of cases with diffuse GC, 11.2% (28/251) of cases with intestinal GC, 7.3% (7/97) of cases with mixed GC (=0.0378). PD-L1 expression (CPS> 1) was found in 42.3% (11/26) of cases with diffuse GC, 59.4% (35/59) of cases with intestinal GC, 27.3% (9/33) of cases with mixed GC (=0.006). In poorly cohesive/signet ring cell cancer MSI occurred in 2.5% (2/79) of cases; HER2 overexpression - in 2.9% (2/68) of cases; PD-L1 (CPS> 1) - in 42.1% (8/19) of cases.
[CONCLUSION] Our study demonstrated that in diffuse and poorly cohesive/signet ring cell GC the frequency of occurrence of the above clinically significant tumor biomarkers is lower compared to intestinal/mixed GC.
[OBJECTIVE] To study the frequency of HER2, MSI / dMMR and PD-L1 (CPS) in patients with operable GC depending on the tumor type according to P. Lauren.
[MATERIAL AND METHODS] The study included 600 patients with GC who underwent radical surgical treatment at the N.N. Blokhin National Medical Research Center of Oncology from 2018 to 2023.
[RESULTS] In the study, the proportion of diffuse GC was 21.5% (120/600). HER2 overexpression was found in 5.2% (5/96) of cases with diffuse GC, 20.4% (37/181) of cases with intestinal GC, 10.1% (7/69) of cases with mixed GC (=0.0029). The incidence of MSI was 3.3% (4/120) of cases with diffuse GC, 11.2% (28/251) of cases with intestinal GC, 7.3% (7/97) of cases with mixed GC (=0.0378). PD-L1 expression (CPS> 1) was found in 42.3% (11/26) of cases with diffuse GC, 59.4% (35/59) of cases with intestinal GC, 27.3% (9/33) of cases with mixed GC (=0.006). In poorly cohesive/signet ring cell cancer MSI occurred in 2.5% (2/79) of cases; HER2 overexpression - in 2.9% (2/68) of cases; PD-L1 (CPS> 1) - in 42.1% (8/19) of cases.
[CONCLUSION] Our study demonstrated that in diffuse and poorly cohesive/signet ring cell GC the frequency of occurrence of the above clinically significant tumor biomarkers is lower compared to intestinal/mixed GC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.